Basic Quilonum SR Information

• International Nonproprietary Name (INN): Lithium carbonate (Lithiumum carbonicum in some European listings)
• Brand names available in Australia: Quilonum SR
• ATC Code: N05AN01
• Forms & dosages: 450 mg controlled-release tablets
• Manufacturers in Australia: Various generic manufacturers supply lithium carbonate
• Registration status in Australia: Prescription only (Rx)
• OTC / Rx classification: Prescription only (Rx)

Latest Research Highlights

Recent studies have reaffirmed the efficacy of lithium carbonate, marketed internationally as Quilonum SR, in managing bipolar disorder. Australian research puts a spotlight on its pivotal role in preventing both manic and depressive episodes. A 2023 meta-analysis showed that lithium is profoundly superior to placebo when it comes to mood stabilization, evidenced by a nearly 50% reduction in relapses among individuals diagnosed with bipolar disorder. The association of lithium with a lower suicide risk is particularly significant in rural Australian populations, where access to mental health services is often limited. Regular monitoring is essential for ensuring that serum lithium levels remain within the therapeutic range of 0.6-1.2 mEq/L. **Data highlight:** A comparison of randomised controlled trial outcomes showcases notable side effects when dosed correctly. Key findings from studies illustrate:

Study Type	Outcome	Year
Meta-analysis	50% relapse reduction	2023
RCT	Decreased suicide risk	2022

The evidence underscores the integration of Quilonum SR into Australian mental health treatment plans, particularly when prescribed under PBS guidelines. Insights from these findings also highlight the need for continuous monitoring to account for demographic differences, ensuring culturally appropriate care. Regardless of the context, understanding what is Quilonum SR used for is integral for both health professionals and patients. **Key Points to Remember:** - **Quilonum SR 450mg** is the primary form used for treatment. - While there are **quilonum sr side effects**, they can be mitigated with proper monitoring and dosage adjustments. - Its effectiveness in mood stabilization makes it a crucial component in treating bipolar disorder.

Composition & Brand Landscape

Quilonum SR is recognised for its active ingredient, lithium carbonate, marked under the ATC code N05AN01, which identifies it as a mood stabiliser. This classification highlights its critical role in managing conditions such as bipolar disorder. In Australia, it’s predominantly found in a controlled-release formulation. This specific design promotes steady serum levels, offering a smoother therapeutic experience and effectively reducing side effects often linked with peak concentration levels.

The availability of Quilonum SR as a controlled-release option is key for those requiring ongoing treatment. It allows for easier management of medication schedules and enhances overall adherence. The significance of this adaptability shines through particularly for patients in long-term management of bipolar disorder. Understanding how critical this stability is can help patients and healthcare providers make informed choices.

Within the Australian pharmaceutical landscape, Quilonum SR stands out among other products like Lithobid and various generics available under the PBS framework. Generics provide a more affordable pathway for patients without sacrificing effectiveness. Local community pharmacies such as Chemist Warehouse and TerryWhite Chemmart typically stock these medications, reflecting a robust supply chain aimed at accessibility.

Packaged in 450 mg controlled-release tablets, Australia shows a clear commitment to enhancing treatment efficiency through strategic formulation choices. This aligns well with the cultural expectations surrounding affordability in healthcare, ensuring patients can access essential treatments without overwhelming financial burdens.

In addition to Quilonum SR, the Australian market boasts a variety of other brands. However, the essential features of Quilonum SR, particularly its controlled-release capability, provide unique advantages that many patients find beneficial. Monitoring and maintaining stable lithium levels is vital, and Quilonum SR plays a crucial role in this regard.

Interactions Overview

When considering the use of Quilonum SR, awareness of potential interactions is crucial. Patients often wonder how daily habits, such as diet and substances, affect their treatment.

Food and drink alterations, particularly alcohol and significant caffeine consumption, can exacerbate side effects like dehydration and increased lithium levels.

Healthcare professionals often advise maintaining a consistent sodium intake and adequate hydration since these factors can significantly influence lithium pharmacokinetics. Ensuring stability in these areas can promote better treatment outcomes.

Drug Interactions to Watch Out For

Drug interactions also pose a significant concern. Patients taking diuretics or NSAIDs may face an increased risk of lithium toxicity. These substances can alter renal clearance, which is vital for the excretion of lithium from the body.

Here are some important considerations for patients:

• Regular evaluations of kidney function are essential.
• Monitoring lithium levels can help avoid toxicity.
• Adjustments to medications should be discussed with doctors.

Healthcare providers are encouraged to utilize TGA data and e-health systems to stay updated on emerging findings around drug interactions. This commitment to continuous learning is fundamental for optimising patient care.

Pharmacists play a crucial role by offering counselling regarding lifestyle changes. Providing accessible information on safe practices helps mitigate risks associated with potential interactions. This collaboration fosters a more informed patient community, empowering individuals on their health journeys.

Ultimately, being aware of Quilonum SR interactions within Australian counselling practices underscores the collective effort in mental health management. Patients equipped with the right resources can make informed decisions that contribute to successful treatment outcomes.

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Pert	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Hobart	Tasmania	5–9 days
Canberra	Australian Capital Territory	5–7 days
Gold Coast	Queensland	5–9 days
Wollongong	New South Wales	5–9 days
Geelong	Victoria	5–9 days
Newcastle	New South Wales	5–9 days
Cairns	Queensland	5–9 days
Sunshine Coast	Queensland	5–9 days
Launceston	Tasmania	5–9 days
Ballarat	Victoria	5–9 days